Yahoo Web Search

Sign In

Search results

  1. alexion.comAlexion

    Alexion develops and provides innovative medicines for people with rare and devastating conditions. Learn about their stories, products, offices, and how they work with the rare disease community.

    • Our Inspiration

      Living With Rare Diseases. Rare diseases can be devastating...

    • Our Medicines

      References: Noris M, Remuzzi G. Atypical hemolytic-uremic...

    • Our Research

      Alexion is committed to collaborating with researchers on...

    • Our Commitment

      Applicants own and control the activity and any related...

    • Our Company

      At Alexion, our passion drives us to continuously innovate...

    • Your Career

      Join one of the world's leading rare disease...

    • News & Media

      Alexion Pharmaceuticals, Inc. provides this data for...

    • Contact Us

      Contact Us. In order to direct your inquiry to the correct...

  2. en.wikipedia.org › wiki › Alexion_PharmaceuticalsAlexion Pharmaceuticals - Wikipedia

    Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

  3. alexion.com › your-career › career-opportunitiesCareer Opportunities | Alexion

    Alexion is a global leader in developing and delivering innovative treatments for people living with rare and devastating diseases. Explore job openings, culture, benefits, and stories of Alexion employees and patients.

  4. alexion.com › our-company › about-usAbout | Alexion

    Alexion is a biopharmaceutical company that develops and delivers medicines for people with rare and devastating diseases. Learn about our history, values, culture, and achievements in transforming lives every day.

  5. Videos

    View all

  6. www.astrazeneca.com › acquisition-of-alexion-completedAcquisition of Alexion completed - AstraZeneca

    Jul 21, 2021 · AstraZeneca announces the closing of the deal to buy Alexion, a biotech company focused on rare diseases, for $13.3bn in cash and shares. The acquisition expands AstraZeneca's presence in immunology and complement-biology, and creates a new growth opportunity in rare diseases.

  7. media.alexion.com › news-releases › news-release-detailsAlexion, AstraZeneca Rare Disease, enters agreement with Pfizer...

    Jul 28, 2023 · The agreement expands Alexion and AstraZeneca's genomic medicine capabilities and pipeline with novel AAV capsids and programmes for rare diseases. The transaction is expected to close in Q3 2023 and is valued at up to $1bn plus royalties.

  8. www.astrazeneca.com › media-centre › press-releasesAstraZeneca receives US clearance of proposed acquisition of...

    Apr 16, 2021 · AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review. This follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.